by John Conrad | Dec 3, 2024 | Member News
COUR Pharmaceuticals has secured a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize its tolerogenic nanoparticle treatments for autoimmune conditions. The partnership, announced via press release...
by John Conrad | Oct 30, 2024 | Member News, NewsBrief
Pathos AI, a Chicago-based biotech startup, has secured $62 million in Series C funding to advance its AI-driven approach to drug development, according to a Tuesday press release. The funding news, also covered by Katherine Davis of Crain’s Chicago Business and...
by John Conrad | Oct 28, 2024 | Member News, NewsBrief
AbbVie announced today it will acquire Boston-based Aliada Therapeutics in a $1.4 billion cash deal, expanding its presence in neuroscience and Alzheimer’s disease research. The acquisition gives AbbVie access to Aliada’s novel blood-brain barrier crossing...
by John Conrad | Oct 28, 2024 | Member News, NewsBrief
Chicago-headquartered Iterum Therapeutics (Nasdaq: ITRM) has received U.S. Food and Drug Administration (FDA) approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited...
by John Conrad | Oct 10, 2024 | Member News
Vanqua Bio has announced positive interim results from its Phase 1 clinical trial of VQ-101, a novel drug designed to treat GBA-Parkinson’s and related disorders. This breakthrough could potentially slow or even halt the progression of Parkinson’s disease,...
by John Conrad | Oct 8, 2024 | Member News
Astellas Pharma Inc. and AviadoBio Ltd. have announced an exclusive option and license agreement for AVB-101, a promising gene therapy currently in Phase 1/2 clinical trials. This collaboration marks a significant step forward in addressing the urgent need for...
